APEI earnings analysis
What we found in APEI's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
The provided 10-Q extract does not include the income statement, balance sheet, cash-flow statement, segment disclosures, or MD&A, so current-quarter revenue, margins, EPS, cash flow, and operating trends cannot be quantified from the filing text supplied. The filing reports effective controls, no material legal proceedings, and continued share repurchases, but highlights sensitivity of annual interest expense to Term SOFR and a pending Health+ leadership transition. No explicit numeric guidance is provided, and management states there were no material changes to the formal risk factors.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Share Repurchases Continue
- The company repurchased 70,365 shares during April 2026 at an average price of $56.86, leaving approximately $44,999,077 available under the $50.0 million authorization.
- Controls Remained Effective
- Management concluded that disclosure controls and procedures were effective as of June 30, 2026, and reported no material changes to internal control over financial reporting.
- Limited Investment-Market Exposure
- The company reported no material derivative financial instruments as of June 30, 2026 and stated that a 10% change in interest rates would not materially affect the fair value of its short-term investment portfolio.
- No Material Legal Proceedings
- The filing states that no material legal proceedings are currently pending.
- Short-Duration Investment Portfolio
- The company said its cash and short-term investments are held in bank deposits, money market funds, U.S. Treasury bills, and investment-grade commercial paper, with maturities of less than one year for the short-term portfolio.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Floating-Rate Interest Expense
- For every 100-basis-point increase in Term SOFR, the company would incur an incremental $0.9 million in annual interest expense, excluding any offset from its interest-rate cap agreement.
- Uninsured Bank Deposits
- Bank deposits exceed federally insured limits, creating potential concentration and counterparty exposure even though the company states it has historically experienced no losses in those accounts.
- Health+ Leadership Transition
- The President of RU will leave effective August 20, 2026, and the company has begun identifying the next leader of its Health+ division, creating execution and leadership-transition risk.
- Capital Allocation and Liquidity
- The company authorized up to $50.0 million for share repurchases and had used $5,000,643 of that authorization by June 30, 2026, potentially reducing liquidity available for other corporate purposes.
- No Formal Risk-Factor Updates
- The filing states that there have been no material changes to the risk factors in the Annual Report; therefore, no new formal risk-factor updates were identified versus the prior filing.
What they said about what is next.
The provided 10-Q extract contains no explicit numeric revenue or EPS outlook. No change to prior guidance can be determined from the filing.
The filing reads about the same as the one before it.
What came before.
- 10-Q · May 11, 2026
- American Public Education, Inc. reported a 6.2% revenue increase year-over-year to $174.7 million for Q1 2026, driven by higher net course registrations in both segments. Net income surged to $17.7 million from $8.9…
- 10-K · March 12, 2026
- American Public Education (APEI) reported full-year 2025 revenue of $648.862 million, up $24.3 million or 3.9% from 2024, with net income of $31.557 million and diluted EPS of $1.36. The company generated $61.965…
- 10-Q · November 10, 2025
- American Public Education reported Q3 revenue of $163,215 (thousands), up from $153,122 in Q3 2024, with operating income before interest and taxes rising to $9,697 (thousands) and diluted EPS of $0.30. Liquidity…
- 10-Q · August 6, 2025
- APEI reported Q2 revenue of $162,766,000, up $9,871,000 (6.5%) versus Q2 2024 and modestly below the prior quarter. Operating income improved materially year-over-year to $7,025,000 (4.3% margin) but reported diluted…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing APEI makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever